Jules Bouget
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jules Bouget has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Aurélie Hirschler
Laboratoire de Spectrométrie de Masse Bio-Organique (LSMBO), IPHC, UMR 7178, Université de Strasbourg, CNRS, 67087 Strasbourg, France
1 shared publication - Barbara Gorda
Institut de Recherche en Infectiologie de Montpellier (IRIM), Univ Montpellier, CNRS, 1919 route de Mende, Montpellier, France
1 shared publication - Christine Carapito
BioOrganic Mass Spectrometry Laboratory (LSMBO), IPHC UMR 7178, University of Strasbourg, CNRS, Strasbourg, France
1 shared publication - Corentin Bernou
Institut de Recherche en Infectiologie de Montpellier (IRIM), Univ Montpellier, CNRS, 1919 route de Mende, Montpellier, France
1 shared publication Diana Brychka
Institut de Recherche en Infectiologie de Montpellier (IRIM), Univ Montpellier, CNRS, 1919 route de Mende, Montpellier, France
1 shared publicationEmma Partiot
Institut de Recherche en Infectiologie de Montpellier (IRIM), Univ Montpellier, CNRS, 1919 route de Mende, Montpellier, France
1 shared publication
Latest Publications
- Open Access
- 1 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Pharmacological targeting of bunyavirus-induced synaptic impairment prevents neuronal hyperexcitability
Orthobunyaviruses are linked to a broad spectrum of neurological disorders. However, the molecular determinants governing bunyavirus neuropathogenesis remain poorly understood, precluding the identification of drugs able to alleviate virus-induced neuronal dysfunctions. Here, we show that the prevalent, yet neglected, orthobunyavirus Ťahyňa virus (TAHV) disrupts neuronal integrity and proteostasis in human cerebral organoids (hCO), significantly decreasing synaptic protein expression and density. Moreover, TAHV-induced synaptic remodeling is associated with perturbed local field potential in organotypic cultures of human post-mortem adult brain explants (OPAB) and higher expression of the metabotropic Glutamate receptor 1 (mGluR1) in mice in the absence of overt neurological disease or neuroinflammation. Using proteome-based network medicine, we identified gabapentin as a therapeutic candidate that restores neurotransmitter receptor levels back to baseline in mice, and prevents TAHV-induced hyperexcitability in OPAB. Together, our data highlights the underappreciated neuropathological potential of a neglected orthobunyavirus, that interferes with neural integrity and neurotransmission, while neuromodulatory interventions may help to preserve cerebral functions.
- 1 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessPharmacological targeting of bunyavirus-induced synaptic impairment prevents neuronal hyperexcitability
Orthobunyaviruses are linked to a broad spectrum of neurological disorders. However, the molecular determinants governing bunyavirus neuropathogenesis remain poorly understood, precluding the identification of drugs able to alleviate virus-induced neuronal dysfunctions. Here, we show that the prevalent, yet neglected, orthobunyavirus Ťahyňa virus (TAHV) disrupts neuronal integrity and proteostasis in human cerebral organoids (hCO), significantly decreasing synaptic protein expression and density. Moreover, TAHV-induced synaptic remodeling is associated with perturbed local field potential in organotypic cultures of human post-mortem adult brain explants (OPAB) and higher expression of the metabotropic Glutamate receptor 1 (mGluR1) in mice in the absence of overt neurological disease or neuroinflammation. Using proteome-based network medicine, we identified gabapentin as a therapeutic candidate that restores neurotransmitter receptor levels back to baseline in mice, and prevents TAHV-induced hyperexcitability in OPAB. Together, our data highlights the underappreciated neuropathological potential of a neglected orthobunyavirus, that interferes with neural integrity and neurotransmission, while neuromodulatory interventions may help to preserve cerebral functions.